Are there ongoing ibogaine clinical trials in 2026? Yes, but access remains extremely limited, and full FDA approval is years away. However, the landscape of ibogaine research is shifting rapidly, driven by new federal directives and state-funded initiatives. In April 2026, a presidential Executive Order aimed at accelerating treatments for serious mental illness brought psychedelics, including ibogaine compounds, into the national spotlight. While this marks a historic milestone for psychedelic medicine, the reality for patients seeking immediate relief from substance use disorder remains complex. Waiting for a U.S. clinical trial involves navigating strict eligibility requirements and long timelines, whereas seeking treatment abroad offers immediate access but requires careful vetting of medical protocols.
What the April 2026 Executive Order Means for Ibogaine
The recent federal directive has sparked significant interest, but understanding its practical implications is necessary for patients weighing their options.
The Executive Order
On April 18, 2026, the White House issued an Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness.” This directive instructs the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) to establish pathways that allow eligible patients to access investigational psychedelic drugs. The order specifically mentions ibogaine compounds by name, signaling a top-down push to evaluate these medicines for conditions that have not responded to standard therapies.
DemeRx IND Clearance
Following the Executive Order, the FDA cleared DemeRx’s Investigational New Drug (IND) application for DMX-1001, an oral formulation of noribogaine. This clearance allows DemeRx to advance into Phase 2 clinical trials for alcohol use disorder (AUD) in 2027, marking the first time the FDA has authorized a U.S. clinical study of an ibogaine derivative. While this represents a major step forward for domestic research, it does not equate to immediate public access or approval.
Priority Review Vouchers
The Executive Order also directs the FDA to issue Commissioner’s National Priority Vouchers for appropriate psychedelic drugs that hold Breakthrough Therapy designation. These vouchers are designed to accelerate the regulatory review process once a drug completes its required trials, thereby compressing what can otherwise be a 10- to 12-month review window. Although this could shorten the final review timeline, the drug must still pass rigorous Phase 2 and Phase 3 clinical trials before a voucher becomes relevant.
The Right-to-Try Pathway: Do You Qualify for Ibogaine?
The Right to Try Act offers a potential pathway for patients who cannot wait for full FDA approval, but its application to ibogaine is far more limited than many patients realize.
What is Right to Try?
The federal Right to Try Act allows patients diagnosed with life-threatening diseases or conditions to access unapproved, investigational treatments. This pathway is intended for individuals who have exhausted all approved treatment options and are unable to participate in a formal clinical trial. The treating physician must certify the patient’s eligibility and obtain written informed consent before any investigational drug can be administered.
Eligibility Requirements
To qualify under the Right to Try Act, the experimental drug must meet strict criteria. The medication must have successfully completed a Phase 1 clinical trial and remain the subject of an active, ongoing clinical trial intended to form the primary basis for an FDA approval claim. A physician must also certify that the patient has no other viable approved options and that the patient cannot participate in an existing trial.
The Reality for Ibogaine
Most patients currently do not qualify to receive ibogaine under the Right to Try Act. Although the Executive Order encourages the use of this pathway, ibogaine and its derivatives are still in the early stages of the FDA process, primarily Phase 1 and early Phase 2. The FDA’s ongoing concerns regarding cardiac safety, specifically QT interval prolongation, have historically slowed ibogaine research, and legal analysts have noted that ibogaine has arguably not yet met the basic safety requirements necessary for Right to Try eligibility.
Active Ibogaine Clinical Trials and University Research in California
University-led research is expanding across the country, but participation in these studies requires navigating specific institutional protocols and eligibility requirements.
Current Research Landscape
A search of the NIH Clinical Trials page reveals a number of active studies investigating ibogaine for conditions such as opioid use disorder (OUD) and post-traumatic stress disorder. State-funded programs in Texas, Kentucky, Arizona, and Mississippi are also generating IRB-approved, real-world evidence that will eventually feed into the FDA’s review process. These trials enforce strict inclusion and exclusion criteria, and patients with a history of cardiac issues, certain psychiatric conditions, or those taking specific medications are typically excluded from participation.
UC Irvine Study (MIND-OUD)
The University of California, Irvine is conducting a notable observational study led by Dr. Richard E. Harris. The “Mapping Ibogaine Neural Dynamics in Opioid Use Disorder” (MIND-OUD) study aims to understand how the medicine affects the brain in patients with moderate-to-severe opioid use disorder.
Researchers use magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG) to measure brain activity, connectivity, and neurochemical changes before and after ibogaine treatment. The team hypothesizes that post-treatment scans will show reduced brain responses to opioid cues and lower glutamate levels in regions associated with craving.
UC Irvine does not administer the ibogaine. Participants must independently schedule and pay for their treatment at a licensed clinic outside the United States, such as those operating legally in Mexico. The university research team handles only the pre-treatment and post-treatment imaging and psychological assessments, making this an ideal study for patients already planning to seek treatment abroad.
How to Apply
Patients interested in participating can search clinicaltrials.gov by entering “ibogaine” and filtering by status to find actively recruiting studies. From there, contact the listed research coordinators directly to determine whether you meet the eligibility criteria. However, enrollment is competitive, waiting periods are often long, and many observational trials require patients to secure their own treatment abroad before the university team can conduct its assessments.
FDA Approval Timeline: Why Ibogaine is Still Years Away
Understanding the regulatory process clarifies why domestic access to ibogaine will not happen overnight, even with the Executive Order in place.
The Clinical Trial Phases
The FDA requires new drugs to pass through three distinct phases of clinical trials before approval. Phase 1 tests safety and dosage in a small group of healthy volunteers, typically 20 to 80 participants. Phase 2 evaluates efficacy and side effects in a larger group of patients with the target condition, usually 100 to 300 people. Phase 3 involves large-scale monitoring across multiple sites, often involving 1,000 or more patients, to confirm effectiveness and identify rare adverse reactions before a New Drug Application (NDA) can be submitted.
Current Status
Ibogaine and derivatives like noribogaine remain in the early stages of this process. Most active U.S. research involves Phase 1 or early Phase 2 trials, with DemeRx’s DMX-1001 representing the furthest-along domestic program. The data gathered from these studies will determine whether the compounds can safely progress to large-scale Phase 3 trials, which are the gateway to NDA submission.
Expected Timeline
Despite the momentum generated by the Executive Order and state-level funding, full FDA approval is likely several years away. Regulatory analysts project that Phase 2b and Phase 3 pivotal trials could launch between 2027 and 2028, with an NDA submission window opening no earlier than 2029 or 2030. Even after FDA approval, the DEA must then reschedule ibogaine from Schedule I, a process that adds further time, though the Executive Order directs the Attorney General to complete that review as quickly as practicable.
Ibogaine Treatment in Mexico vs. Waiting for FDA Approval
For individuals facing severe substance use disorder today, waiting years for domestic approval is often not a viable option.
The Regulatory Gap
The long FDA timeline creates a significant gap between the current need for effective interventions and the availability of legal U.S. treatments. Patients battling opioid dependency, severe trauma, or treatment-resistant conditions require help now, not in 2030. That gap is precisely why thousands of Americans, including veterans and first responders, have already traveled to Mexico for medically supervised ibogaine treatment.
Treatment in Mexico
Patients frequently travel to Mexico, where ibogaine is unregulated and can be administered legally in clinical settings. This allows individuals to access the medicine immediately, provided they select a facility that adheres to rigorous medical standards. Reputable clinics in Mexico follow the same cardiac screening, progressive dosing, and 24/7 supervision protocols that any future FDA-approved U.S. program would be required to implement, ensuring that treatment is consistent, dependable, and safe.
Cost and Accessibility
The cost of treatment in Mexico typically ranges from $5,000 to $20,000+ depending on the facility, required detox duration, and medical protocols. Future U.S. treatments, once approved, will likely be far more expensive due to clinical overhead and regulatory compliance costs, and insurance coverage remains uncertain. Mexican clinics offer immediate availability for those who qualify medically, compared to a years-long wait for domestic approval and the narrow eligibility windows of current clinical trials.
Experience Ibogaine’s Medical Protocols
Experience Ibogaine sets the standard for safe and most affordable, compassionate care in Mexico. The clinic implements clinical-grade safety measures at every stage of the process, from the first consultation through post-treatment aftercare.
- Pre-treatment protocols include comprehensive cardiac screening with EKGs, a full cardiologist evaluation, and complete bloodwork covering liver function, electrolytes, and urinalysis.
- The medical team uses progressive dosing protocols to mitigate cardiac risk, and a physician provides 24/7 supervision with emergency medical equipment available on-site throughout the treatment.
- Patients also receive two booster doses to take home, which help sustain the brain’s noribogaine levels during the critical post-treatment window.
Frequently Asked Questions (FAQs)
No. Ibogaine is classified as a Schedule I controlled substance under federal law, making it illegal to possess, distribute, or administer outside of FDA-approved research settings. Some states have passed legislation to fund clinical research, but that does not change the federal classification.
The cost generally ranges from $5,000 to $20,000+. The final price depends on the patient’s specific detox requirements, the clinic they choose, the length of stay, and the medical protocols necessary for their safety. U.S. medical insurance does not cover ibogaine treatment, as the drug is not FDA-approved.
Yes, if you meet the strict eligibility criteria. Texas has committed $50 million to the Ibogaine Medicina for PTSD, Addiction, and Cognitive Trauma (IMPACT) consortium led by UTHealth Houston, and UC Irvine in California is conducting the MIND-OUD observational study. Keep in mind that some observational trials require you to obtain treatment outside the U.S. at a licensed clinic before the university team can conduct its brain imaging assessments.
Ibogaine is the primary psychoactive alkaloid extracted from the African iboga plant. Noribogaine is its active metabolite, produced when the liver processes ibogaine. Noribogaine stays in the system longer and is responsible for much of the treatment’s sustained effect on mu-opioid receptor regulation and cravings. DemeRx is currently developing DMX-1001, an oral noribogaine formulation, for Phase 2 clinical trials targeting alcohol use disorder.
References
- “Accelerating Medical Treatments for Serious Mental Illness.” The White House, April 18, 2026.
- June 8, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/.
- Vincent, K. “DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD).” Business Wire, April 22, 2026.
- June 8, 2026. https://www.businesswire.com/news/home/20260422651767/en/DemeRx-Announces-FDA-Acceptance-of-IND-Application-to-Advance-DMX-1001-for-the-Treatment-of-Alcohol-Use-Disorder-AUD.
- “FDA Fact Sheet.” U.S. Food and Drug Administration.
- June 8, 2026. https://www.fda.gov/media/133864/download.
- Brunt, T. “Rare but Relevant: Ibogaine and Cardiovascular Complications-Prolonged QT Interval and Ventricular Arrhythmias.” Addiction, June, 2026.
- June 8, 2026. https://read.qxmd.com/read/41560340/rare-but-relevant-ibogaine-and-cardiovascular-complications-prolonged-qt-interval-and-ventricular-arrhythmias.
- Grahame, I. “New Front Runners in Psychedelic Research Emerge, as Texas Put 50 Million into Ibogaine R&D.” Drug Science, Feb 11, 2026.
- June 8, 2026. https://www.drugscience.org.uk/texas-ibogaine.
- “Legislation and Advocacy…” Americans for Ibogaine.
- June 8, 2026. https://www.americansforibogaine.org/legislation/.
- Harris, R. “Mapping Ibogaine Neural Dynamics in Opioid Use Disorder (MIND-OUD).” University of California, Irvine, May, 18, 2026. https://clinicaltrials.gov/study/NCT07226570?intr=ibogaine&viewType=Card&locStr=United%20States&country=US&rank=2.
- “Step 3: Clinical Research.” FDA, January, 2018. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research.
- “New Drug Application (NDA).” FDA, January, 2022. https://www.fda.gov/drugs/types-applications/new-drug-application-nda.
- “UTHealth Houston, in Collaboration with UTMB Health, Awarded $50 Million by the State of Texas to Lead Ibogaine Clinical Trials.” UTHealth Houston, December, 2025. https://www.uth.edu/news/story/uthealth-houston-in-collaboration-with-utmb-health-awarded-50-million-by-the-state-of-texas-to-lead-ibogaine-clinical-trials.
